CoChat

Individual Variation in Lipidomic Profiles of Healthy Subjects in Response to Omega-3 Fatty Acids

Open access

The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Conflicting findings in both interventional and observational studies have resulted in a lack of consensus on the benefits of ω3 fatty acids in reducing disease risk. This may be due to individual variability in response. We used a multi-platform lipidomic approach to investigate both the consistent and inconsistent responses of individuals comprehensively to a defined ω3 intervention. METHODS: The lipidomic profile including fatty acids, lipid classes, lipoprotein distribution, and oxylipins was examined multi- and uni-variately in 12 healthy subjects pre vs. post six weeks of ω3 fatty acids (1.9 g/d eicosapentaenoic acid [EPA] and 1.5 g/d docosahexaenoic acid [DHA]). RESULTS: Total lipidomic and oxylipin profiles were significantly different pre vs. post treatment across all subjects (p=0.00007 and p=0.00002 respectively). There was a strong correlation between oxylipin profiles and EPA and DHA incorporated into different lipid classes (r(2)=0.93). However, strikingly divergent responses among individuals were also observed. Both ω3 and ω6 fatty acid metabolites displayed a large degree of variation among the subjects. For example, in half of the subjects, two arachidonic acid cyclooxygenase products, prostaglandin E2 (PGE2) and thromboxane B2 (TXB2), and a lipoxygenase product, 12-hydroxyeicosatetraenoic acid (12-HETE) significantly decreased post intervention, whereas in the other half they either did not change or increased. The EPA lipoxygenase metabolite 12-hydroxyeicosapentaenoic acid (12-HEPE) varied among subjects from an 82% decrease to a 5,000% increase. CONCLUSIONS: Our results show that certain defined responses to ω3 fatty acid intervention were consistent across all subjects. However, there was also a high degree of inter-individual variability in certain aspects of lipid metabolism. This lipidomic based phenotyping approach demonstrated that individual responsiveness to ω3 fatty acids is highly variable and measurable, and could be used as a means to assess the effectiveness of ω3 interventions in modifying disease risk and determining metabolic phenotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0076575

Cites

59 of 60 references verified1 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Lipidomic (A) and lipoprotein (B) profiles summarized as scores (t(1) and to(1)) calculated by OPLS-DA. All participants displayed altered lipidomic profiles pre (grey circles) vs. post (black circles) supplementation (A). Furthermore, the subjects displayed gender-specific lipoprotein profiles, female (black circles) and male (grey circles), both before and after intervention (B).
Figure 1 Lipidomic (A) and lipoprotein (B) profiles summarized as scores (t(1) and to(1)) calculated by OPLS-DA. All participants displayed altered lipidomic profiles pre (grey circles) vs. post (black circles) supplementation (A). Furthermore, the subjects displayed gender-specific lipoprotein profiles, female (black circles) and male (grey circles), both before and after intervention (B).CC BY · PubMed Central
Figure 2 PCA score plot of the 35 variables most influential to the orthogonal component in Figure 1a. There was a pattern among the data separating subject 202 and 220 (black circles) from the rest of the subjects (grey circles).
Figure 2 PCA score plot of the 35 variables most influential to the orthogonal component in Figure 1a. There was a pattern among the data separating subject 202 and 220 (black circles) from the rest of the subjects (grey circles).CC BY · PubMed Central
Figure 3 Contribution of each oxylipin to the pre (below origin) and post (above origin) profiles calculated by OPLS-DA (A). The CYP pathway (black) was the most responsive pathway, followed by the LOX pathway (light grey), and COX pathway (dark grey). Correlation between the oxylipin profiles and DHA and EPA incorporated in different lipid classes (B).
Figure 3 Contribution of each oxylipin to the pre (below origin) and post (above origin) profiles calculated by OPLS-DA (A). The CYP pathway (black) was the most responsive pathway, followed by the LOX pathway (light grey), and COX pathway (dark grey). Correlation between the oxylipin profiles and DHA and EPA incorporated in different lipid classes (B).CC BY · PubMed Central
Figure 4 Bar graphs of each individual subject’s % change in the following arachidonic acid (ARA, 20:4n6) metabolites (subjects ordered by direction and magnitude of response on x axis): A) the cyclooxygenase (COX) metabolite prostaglandin E2 (PGE2); B) the COX metabolite thromboxane B2 (TXB2); C) ARA concentrations within the phosphatidylethanolamine (PE) lipid class; and D) the lipoxygenase metabolite 12-hidroxyeicosatetraenoic acid (12-HETE).
Figure 4 Bar graphs of each individual subject’s % change in the following arachidonic acid (ARA, 20:4n6) metabolites (subjects ordered by direction and magnitude of response on x axis): A) the cyclooxygenase (COX) metabolite prostaglandin E2 (PGE2); B) the COX metabolite thromboxane B2 (TXB2); C) ARA concentrations within the phosphatidylethanolamine (PE) lipid class; and D) the lipoxygenase metabolite 12-hidroxyeicosatetraenoic acid (12-HETE).CC BY · PubMed Central
Figure 5 Correlations between: A) % change in arachidonic acid (ARA, 20:4n6) cyclooxygenase metabolite prostaglandin F2α (PGF2α) and % change in phosphatidylcholine (PC) concentrations of ARA; B) % change in eicosapentaenoic acid (EPA, 20:5n3) soluble epoxide hydrolase (sEH) metabolite 17,18-dihydroxyeicosatrienoic acid (17,18-DiHETE) and % change in triglyceride (TG) concentrations of EPA; C) % change in docosahexaenoic acid (DHA, 22:6n3) sEH metabolite 10,11-dihydroxydocosapentaenoic acid (10,11-DiHDPE) and % change in free fatty acid (FFA) concentrations of DHA; D) % change in PE concentrations of DHA and baseline PE ARA %.
Figure 5 Correlations between: A) % change in arachidonic acid (ARA, 20:4n6) cyclooxygenase metabolite prostaglandin F2α (PGF2α) and % change in phosphatidylcholine (PC) concentrations of ARA; B) % change in eicosapentaenoic acid (EPA, 20:5n3) soluble epoxide hydrolase (sEH) metabolite 17,18-dihydroxyeicosatrienoic acid (17,18-DiHETE) and % change in triglyceride (TG) concentrations of EPA; C) % change in docosahexaenoic acid (DHA, 22:6n3) sEH metabolite 10,11-dihydroxydocosapentaenoic acid (10,11-DiHDPE) and % change in free fatty acid (FFA) concentrations of DHA; D) % change in PE concentrations of DHA and baseline PE ARA %.CC BY · PubMed Central
Figure 6 Bar graphs of each individual subject’s % change in the following eicosapentaenoic acid (EPA, 20:5n3) metabolites (subjects ordered by direction and magnitude of response on x axis): A) the lipoxygenase metabolite 12-hydroxyeicosapentaenoic acid (12-HEPE); B) the soluble epoxide hydrolase (sEH) metabolite 17,18-dihydroxyeicosatrienoic acid (17,18-DiHETE); C) phosphatidylcholine (PC) concentrations of EPA; and D) phosphatidylethanolamine (PE) concentrations of EPA.
Figure 6 Bar graphs of each individual subject’s % change in the following eicosapentaenoic acid (EPA, 20:5n3) metabolites (subjects ordered by direction and magnitude of response on x axis): A) the lipoxygenase metabolite 12-hydroxyeicosapentaenoic acid (12-HEPE); B) the soluble epoxide hydrolase (sEH) metabolite 17,18-dihydroxyeicosatrienoic acid (17,18-DiHETE); C) phosphatidylcholine (PC) concentrations of EPA; and D) phosphatidylethanolamine (PE) concentrations of EPA.CC BY · PubMed Central
Figure 7 Bar graphs of each individual subject’s % change in the following docosahexaenoic acid (DHA, 22:6n3) metabolites (subjects ordered by direction and magnitude of response on x axis): A) the lipoxygenase metabolite 17-hydroxy docosahexaenoic acid (17-HDoHE); B) the soluble epoxide hydrolase (sEH) metabolite 10,11-dihydroxydocosapentaenoic acid (10,11-DiHDPE); C) phosphatidylethanolamine (PE) concentrations of DHA; and D) triglyceride (TG) concentrations of DHA.
Figure 7 Bar graphs of each individual subject’s % change in the following docosahexaenoic acid (DHA, 22:6n3) metabolites (subjects ordered by direction and magnitude of response on x axis): A) the lipoxygenase metabolite 17-hydroxy docosahexaenoic acid (17-HDoHE); B) the soluble epoxide hydrolase (sEH) metabolite 10,11-dihydroxydocosapentaenoic acid (10,11-DiHDPE); C) phosphatidylethanolamine (PE) concentrations of DHA; and D) triglyceride (TG) concentrations of DHA.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 100

Metadata

Authors
Nording, M. L., Yang, J., Georgi, K., Hegedus Karbowski, C., German, J. B., Weiss, R. H., Hogg, R. J., Trygg, J., Hammock, B. D., & Zivkovic, A. M.
Affiliations
  • University of California, Davis (US)
  • UC Davis Comprehensive Cancer Center (US)
  • Sacramento VA Medical Center (US)
  • Umeå University (SE)
Corresponding author
Zivkovic, Angela M.
Venue
PLoS ONE
Published
2013-10-24
Volume
8
Issue
10
Pages
e76575
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2162751353
Cited by
100
References
59
Citations by year
2025: 6 · 2024: 6 · 2023: 1 · 2022: 4 · 2021: 6 · 2020: 13 · 2019: 8 · 2018: 15 · 2017: 12 · 2016: 5 · 2015: 13 · 2014: 10 · 2013: 1
FWCI
8.97
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • California Dairy Research Foundation
  • American Asthma Foundation (R01 ES002710, 09-0269)
  • VINNOVA (2010-02070)
  • Svenska Forskningsrådet Formas (2010-303)
  • National Institutes of Health (DK097154, ES002710, ES011269)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK049368, U24DK097154, DK 097154, DK49368, R01 DK49368)
  • National Institute of Environmental Health Sciences (P42ES004699, P42 ES011269, ES002710, ES011269, P01ES011269, R01ES002710, NIEHS R01 ES002710)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords
omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, lipidomics, oxylipins, interindividual variability, prostaglandin E2, thromboxane B2, 12-hydroxyeicosatetraenoic acid, arachidonic acid metabolites, lipoxygenase metabolites, cyclooxygenase metabolites, healthy volunteers
MeSH terms
Adult, Female, Humans, Lipids, Lipoproteins, Male, Middle Aged, Pilot Projects, Risk Factors, Fatty Acids, Omega-3, Dietary Supplements, Lipid Metabolism, Oxylipins, Metabolomics, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.